Shasun Chemicals & Drugs is engaged in the manufacture and supply of active pharmaceutical ingredients (API)/intermediaries and formulations with a significant presence in anti-inflammatory and anti-ulcerative therapeutic groups. Its product portfolio consists of multiple products in oral solid dosages (OSD) excepting Betalactums, Cytotoxics and steroids besides therapeutic groups such as analgesics/anti-pyretics/NSAIDs, antihistaminics (H1 and H2 blockers), anti-psychotics, anti-epileptics, anti-hypertensivesand other mild active drugs. Headquartered in Chennai, India and with offices in USA and the UK, the company is one of the largest producers of Ibuprofen worldwide and a major producer of Ranitidine in India. The company filed drug master files for about 16 products in more than 22 countries. During 2004-05, the company filed DMFs for drugs such as Sulphazine, Gabapentin and Ibuprofen Sodium with US FDA and Ibuprofen Sodium in about 20 countries in Europe under the mutual recognition procedure (MRP). During 2004-05, the capacity utilisation of Shasun was almost 78 per cent for most products. The company has also entered into agreements to exclusively manufacture and jointly market OSDs in the cardio-vascular (CVS) and central nervous systems (CNS) therapeutic segments. It has entered into strategic marketing arrangement with Glenmark and Alpharma.
Note : SHASUN CHEMICALS AND DRUGS LIMITED Change in Company Name / Symbol. Members of the Exchange are hereby informed that the name of Shasun Chemicals and Drugs Limited shall be changed to Shasun Pharmaceuticals Limited and the trading symbol of the Company be changed from SHASUNCHEM to SHASUNPHAR w.e.f. January 28, 2011
You
should Trade Less But Trade Accurately & this is Achieved with our Tip.
